Using single-cell–resolved spatial transcriptomics (10x Genomics Xenium, 5,000-gene panel) on kidney biopsies from 8 treatment-naïve MPO-ANCA–positive microscopic polyangiitis patients and 4 healthy donors, this study mapped how epitope-diverse anti-MPO autoantibodies organize pathogenic neutrophil–epithelial niches driving glomerulonephritis, and tested whether one-armed anti-MPO antibodies engineered to minimize FcγR engagement could attenuate kidney injury in mouse models.
Spatial profiling identified early peri-glomerular niches of HAVCR1+ injured proximal tubular epithelial cells secreting CXCL6 and CXCL16 that recruited FcγR-high, type II interferon–enriched neutrophils; combinations of 3 monoclonal anti-MPO antibodies targeting distinct MPO epitopes (mAb-A24, mAb-A46, mAb-B88) synergistically enhanced neutrophil ROS production and NET formation and induced pauci-immune crescentic glomerulonephritis in mice, while one-armed variants of these antibodies significantly reduced urinary albumin-to-creatinine ratios and crescent formation (P<0.01) in a passive-transfer AAV model.
Human biopsy data are cross-sectional, so pseudotime trajectories are computational inferences rather than true temporal sequences; the antibody-induced mouse model relies on 129S6 mice with strain-specific heightened neutrophil reactivity, limiting generalizability; the three one-armed antibodies do not cover the full polyclonal anti-MPO repertoire, so therapeutic breadth in human disease is uncertain.
FcγR-dependent neutrophil activation driven by epitope-diverse anti-MPO antibodies appears central to early glomerular injury in ANCA-associated vasculitis, suggesting that disrupting FcγR engagement—rather than simply neutralizing MPO binding—may be a tractable therapeutic strategy. Patients whose MPO-ANCA recognizes multiple epitopes (Hb/Hc regions) had significantly higher Birmingham Vasculitis Activity Scores, which may help stratify disease severity at diagnosis.
Explore related topics